search
Back to results

Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy

Primary Purpose

Wound Infection

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Cefazolin PostOperatively
Cefazolin Preoperatively
Sponsored by
Aultman Health Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Wound Infection focused on measuring vulvectomy, wound infection, wound complication, prophylactic antibiotic, Post-operative wound complications following vulvectomy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • All female patients 18 years of age or older undergoing surgery for vulvar carcinoma (this includes female patients undergoing any form of vulvectomy - radical, vulvectomy without groin node dissection, and partial vulvectomy)
  • Disease State will not affect inclusion in the study. Women with previous surgery for vulvar carcinoma will be included as will those undergoing initial operation.
  • Number of subjects: 160

Exclusion Criteria:

  • Women simultaneously undergoing treatment for other forms of cancer
  • Women under the age of 18
  • Pregnant patients

Sites / Locations

  • Aultman Health Foundation

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Cefazolin Preoperatively

Cefazolin Postoperatively

Arm Description

Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision

Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op

Outcomes

Primary Outcome Measures

Wound Complications
Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.

Secondary Outcome Measures

Full Information

First Posted
October 25, 2007
Last Updated
September 18, 2018
Sponsor
Aultman Health Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00550290
Brief Title
Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
Official Title
Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
April 2009 (Actual)
Study Completion Date
April 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aultman Health Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This randomized prospective study will specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy.
Detailed Description
Infectious morbidity in gynecologic oncology has not been thoroughly investigated to date. Included in the literature are several studies that highlight substantial numbers of post-surgical infectious complications. Specifically among patients undergoing radical vulvectomy, the incidence of post-operative wound complication is as high as 58%. Surgery is the treatment of choice for vulvar cancer, but few studies establish protocols or management strategies to prevent the complications of post-operative wound infection and breakdown. This proposed randomized prospective study would specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy. This same regimen has been described by a leader in the field of gynecology in his text - TeLinde's Operative Gynecology. This study will utilize two arms - one as the treatment arm utilizing 24 hours of prophylactic antibiotics and the other as control.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Wound Infection
Keywords
vulvectomy, wound infection, wound complication, prophylactic antibiotic, Post-operative wound complications following vulvectomy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cefazolin Preoperatively
Arm Type
Active Comparator
Arm Description
Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
Arm Title
Cefazolin Postoperatively
Arm Type
Experimental
Arm Description
Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
Intervention Type
Drug
Intervention Name(s)
Cefazolin PostOperatively
Other Intervention Name(s)
Ancef, Kefzol
Intervention Description
Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
Intervention Type
Drug
Intervention Name(s)
Cefazolin Preoperatively
Other Intervention Name(s)
Ancef, Kefzol
Intervention Description
Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
Primary Outcome Measure Information:
Title
Wound Complications
Description
Number of participants experiencing wound complications following vulvectomy. The presence of febrile episodes, elevated WBC counts and exam findings will be used to diagnose wound complications.
Time Frame
Two-week post-operative

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All female patients 18 years of age or older undergoing surgery for vulvar carcinoma (this includes female patients undergoing any form of vulvectomy - radical, vulvectomy without groin node dissection, and partial vulvectomy) Disease State will not affect inclusion in the study. Women with previous surgery for vulvar carcinoma will be included as will those undergoing initial operation. Number of subjects: 160 Exclusion Criteria: Women simultaneously undergoing treatment for other forms of cancer Women under the age of 18 Pregnant patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael P Hopkins, MD
Organizational Affiliation
Aultman Health Foundation
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
William T. Schnettler, MD
Organizational Affiliation
Aultman Health Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aultman Health Foundation
City
Canton
State/Province
Ohio
ZIP/Postal Code
44710
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy

We'll reach out to this number within 24 hrs